Overview of Bifonazole

Quick Facts

Property	Description
Active ingredient	Bifonazole (INN)
Form	Cream, Solution, Gel, Powder (Topical)
Pharmacological class	Antifungal Agent (Azole Derivative)
General purpose	To control and eliminate fungal organisms
Origin	Synthetic (Imidazole derivative)

What Type of Medicine is Bifonazole?

Bifonazole is the International Nonproprietary Name (INN) for a synthetic antifungal agent that belongs to the azole derivative class of medicines. This substance is chemically categorized as an Imidazole derivative, a high-level classification within the broader antimycotic drug family. Bifonazole's unique identity is reinforced by its recognized dual mechanism of action, a feature that provides a comprehensive therapeutic approach by inhibiting fungal ergosterol biosynthesis at two separate points, which is a key factor supporting its efficacy profile in dermatological practice.

Composition and Available Forms of Bifonazole

The primary active component in this medicine is Bifonazole, and it is typically formulated as a monotherapy product, although combination versions may exist. For topical administration, the active ingredient is prepared in several dosage forms, including a cream, a solution, a gel, and a powder. Bifonazole is widely available under brand names such as Mycospor and Canespor. These pharmaceutical forms incorporate Bifonazole within a pharmaceutically acceptable base or vehicle to facilitate application and localized absorption, ensuring flexibility for use across various anatomical sites and surface conditions.

General Purpose of Bifonazole Therapy

The general purpose of using Bifonazole is to effectively eliminate or control the growth of specific types of fungal organisms and molds. This benefit stems directly from the drug's mechanism of interfering with the fungal cell membrane; its action is designed to stop the organism from successfully multiplying, thereby resolving the underlying issue of fungal overgrowth. A common use scenario involves addressing persistent superficial infections where the therapeutic goal is the complete control of the organism.

What side effects are possible with Bifonazole?

The official safety documentation for topical bifonazole classifies adverse events primarily within Skin and subcutaneous tissue disorders and Immune system disorders. The majority of documented reactions are localized and reversible, reflecting the drug's topical administration and low systemic absorption.

Adverse Reaction Classification

Classification	Examples of Reactions
Common	Localized effects such as burning sensation, erythema (reddening), skin irritation, and exfoliation (peeling).
Uncommon	Pruritus (itching), eczema, and contact dermatitis.
Frequency Not Known	Allergic dermatitis, urticaria (hives), blistering, dry skin, and administration site pain or peripheral edema.

The most serious adverse reactions listed in regulatory documents are systemic hypersensitivity reactions, which are reported very rarely in post-marketing surveillance.

Regulatory Safety Constraints

Official labels detail constraints for specific populations and circumstances. Use during pregnancy is generally not recommended, especially in the first trimester, and requires a medical assessment of the benefit-risk balance. Due to safety concerns, breast-feeding must be discontinued during the course of treatment. The use of bifonazole in infants and toddlers (under two years of age) is mandated to be under medical supervision.

High-level safety notes include a caution for patients concurrently taking the anticoagulant Warfarin, as co-administration may potentially lead to an increase in the International Normalized Ratio (INR). Furthermore, individuals with a history of hypersensitivity to other imidazole antifungal agents should use bifonazole with caution, as noted in official regulatory information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Bifonazole addresses overdose primarily in the context of accidental exposure. The prescribing information states that no risk of acute intoxication is seen and is unlikely to occur following a single topical application, even when applied to a large skin area.

Documented Manifestations and Emergency Action

Category	Regulatory Statement
Overdose Symptoms	Manifestations are described only following accidental oral ingestion, which may lead to dizziness, nausea, or vomiting if clinical symptoms become apparent.
Emergency Action	Individuals must consult a physician immediately if an overdose is suspected, especially after ingestion.
Antidote Status	No specific antidote is known for Bifonazole.

Accidental oral ingestion, while unlikely to cause severe effects, requires prompt evaluation by a healthcare provider, particularly if systemic symptoms manifest. In such instances, routine supportive measures may be necessary. For example, regulatory labels specify that interventions like gastric lavage should only be considered if clinical symptoms are present and the patient’s airway can be protected adequately. The focus of official guidance is on symptomatic and supportive management, as the documented risk of acute systemic toxicity from the intended topical use is minimal.

Therapeutic Uses of Bifonazole

Bifonazole is relevant within the therapeutic area of dermatological mycoses, the domain covering fungal skin conditions.

This medication is generally used for managing the proliferation of fungal organisms responsible for common skin conditions. It is applicable in conditions involving recurrent or episodic manifestations, such as Tinea pedis (Athlete's foot), Tinea corporis (ringworm), and superficial cutaneous candidiasis (skin yeast infections).

Quick Fact: Symptomatic Support

Bifonazole is relevant in contexts marked by increased discomfort and tension. Its use is focused on easing symptoms related to inflammatory or irritative states, which generally become more disruptive during flare-ups.

In clinical settings where patients experience symptoms that may interfere with routine activities, Bifonazole helps address symptom clusters of intense itching (pruritus), burning, and redness. This supportive relief contributes to easing day-to-day comfort by helping to moderate the visible inflammation and may assist with the appearance of affected skin. The use is aligned with domains involving significant symptom expression.

“It supports the patient during episodes of heightened discomfort by contributing to easing distress and assisting with coping with symptom fluctuations.”

Regulatory References

Healthdirect overview of Bifonazole

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

The eligibility for using topical Bifonazole is strictly defined by regulatory documents, establishing populations for whom use is contraindicated, conditional, or generally permitted.

Eligibility Status	Defined Populations (Regulatory Labeling)
Contraindicated	Individuals with a known hypersensitivity to bifonazole, other imidazole antifungal agents, or any of the formulation's excipients [Source 1.4]. The product is also contraindicated for the treatment of infants with nappy rash [Source 1.4].
Restricted / Conditional Use	Infants and Toddlers (under 2 years of age) must only use the medicine under medical supervision [Source 4.1]. Patients concurrently receiving the anticoagulant warfarin require appropriate and closer monitoring due to limited data suggesting a potential interaction [Source 1.4]. The product should also be used with care on broken skin [Source 1.1].

Age and Physiological State Rules:

Use in adults and older adults is generally permitted under standard labeled conditions, with no specific restrictions for geriatric patients [Source 1.4].

Regarding reproductive status, Bifonazole should not normally be used in pregnancy, with explicit avoidance advised during the first trimester [Source 3.2]. During lactation, the product should not be applied to the chest area, and a decision must be made whether to discontinue breastfeeding or discontinue therapy [Source 1.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bifonazole is characterized by a limited number of clinically significant interactions, reflecting the drug’s topical route of administration and low level of systemic absorption. This information is classified by authoritative government health sources into two main domains.

Drug-Drug Interactions

A specific pharmacokinetic interaction is documented with the class of medicines known as Coumarin Anticoagulants, which includes Warfarin. Although the systemic exposure to Bifonazole is generally low, co-administration may lead to a decreased clearance of the anticoagulant. This interaction can result in an increase in the patient's International Normalized Ratio (INR), indicating elevated systemic exposure and effect of the anticoagulant. Regulatory labeling stipulates a key constraint: the patient's INR must be appropriately monitored throughout the period of concurrent use with Warfarin or other coumarin derivatives to manage this effect.

Drug-Product Interactions

Specific excipients present in the topical Bifonazole formulations are associated with an interaction involving latex products. Official regulatory documents warn that the application of the topical medicine to the genital area may reduce the integrity and effectiveness of latex contraceptive products, such as condoms and diaphragms. This is a physical or chemical incompatibility that results in reduced barrier efficacy.

Mechanism of Action

Dual Mechanism Against Fungal Sterol Synthesis

Bifonazole exerts its primary action by inhibiting two key enzymes within the fungal cell's ergosterol biosynthesis pathway. It targets and blocks Lanosterol 14-alpha-demethylase (CYP51) and, in certain species, also inhibits HMG-CoA reductase. This targeted metabolic interference prevents the necessary conversion of lanosterol into ergosterol, a sterol essential for fungal cell membrane structure. The resulting depletion of ergosterol and the concurrent accumulation of toxic methylated sterols within the cell leads to the disruption of fungal cell integrity and an irreversible shift in cellular function that causes growth cessation or cell death.

Modulation of Local Host Inflammation

Beyond its primary antifungal action, Bifonazole engages a separate mechanism to influence the host's physiological response at the site of activity. This mechanism involves modulating the release and activity of specific localized inflammatory mediators, including influencing the signaling patterns of vascular permeability factors and inflammatory chemokines within the skin tissue. This leads to a modulation of the host's inflammatory response.

Dosage and Administration Information

Official Administration Guidelines

Bifonazole is strictly approved for topical/dermal administration, utilizing dosage forms such as the 1% w/w cream for external use. The standard regimen is a once-daily application, typically carried out in the evening before retiring, as outlined in regulatory instructions.

Procedurally, the skin area must be cleaned and dried thoroughly before a small amount of the formulation is applied thinly to the affected site and gently rubbed in. The application must cover the immediate area surrounding the infection. The medicine's use is constrained by specific durations: for example, Tinea pedis (Athlete's foot) requires a treatment course of three weeks, while Tinea corporis may range from two to three weeks. The full mandated course duration must be completed consistently.

Usage constraints include avoiding the application of occlusive (air-tight) dressings and preventing contact with the eyes or mucosal membranes. If a scheduled daily dose is missed, it should be applied as soon as it is recalled, but users should not apply a double dose. Furthermore, the use of Bifonazole in infants and children is subject to specific medical supervision requirements, which must be followed to ensure proper administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bifonazole

Research on bifonazole has primarily been applied in studies examining patient-reported experiences and how symptoms change over defined time intervals, focusing on common fungal skin conditions. The evidence landscape for this compound is characterized by numerous clinical trials, including comparisons with placebo and other established antifungal agents, to understand how symptoms evolve in conditions presenting with cycles of stability and flare-ups. Findings describe patterns observed across large populations, but research provides context, not individual predictions.

Research for Athlete's Foot (Tinea Pedis)

Studies exploring short-term symptom changes in athlete's foot, or tinea pedis, have evaluated topical bifonazole in various forms. Research examining comparative trials against placebo observed changes in fungal clearance and changes in skin lesions in the group studied with bifonazole. Findings were often similar in studies that monitored bifonazole against other common topical antifungal agents. However, evidence is more limited for the chronic, moccasin-type infection. Comparative data against some newer therapies remains insufficient, and long-term effects regarding the prevention of recurrence are not fully established.

Research for Ringworm, Jock Itch, and Skin Yeast Infections (Dermatophytoses and Cutaneous Candidiasis)

Bifonazole was studied for a broad range of superficial fungal infections, including ringworm and cutaneous yeast infections. Research examined overall rates of mycological clearance and symptom metrics, which often appeared higher in the group studied with bifonazole when compared to placebo. Comparative studies frequently monitored bifonazole against several alternative imidazole antifungal drugs, and findings were often similar. The evidence quality varies across studies, and data are still emerging on its role in certain conditions like seborrhoeic dermatitis. Follow-up durations were limited, meaning data for long-term outcomes remain insufficient.

Research for Pityriasis Versicolor

Studies have explored short-term symptom changes in Pityriasis versicolor, evaluating bifonazole against inactive substances and other topical treatments. Research highlights changes measured during the study period, showing bifonazole use was associated with observed changes in both clinical appearance and microbiological outcomes. When compared to other topical antifungal agents, research generally describes comparable findings. Evidence is limited regarding the use of bifonazole in combination with other therapies, and comparative evidence looking at recurrence rates over extended periods is lacking.

Key Studies & References Health Products Regulatory Authority Public Assessment Report (IPAR) for Canesten Bifonazole Cream (PA1410-083-001)

Frequently Asked Questions (FAQ)

Common questions about Bifonazole (FAQ)

Q: Does Bifonazole treat jock itch?

A: Official regulatory documents confirm the use of bifonazole for treating a group of infections known as dermatophytoses. These conditions include Tinea cruris, which is the medical term for the infection commonly referred to as jock itch.

Q: Is Bifonazole available as a powder or just a cream?

A: According to official product information, bifonazole is documented as being prepared in several topical forms. These dosage forms include a cream, solution, gel, and powder, providing various options for external application.

Q: Is Bifonazole the same as clotrimazole or miconazole?

A: Bifonazole, along with medicines like clotrimazole and miconazole, belongs to the same general pharmacological category of imidazole antifungal agents. Bifonazole is specifically noted in official documents for having a dual mechanism of action, which distinguishes its profile from some other azole drugs.

Q: What should I expect in the first few days of using Bifonazole?

A: In the initial days of using the product, some localized skin reactions at the application site are commonly reported in official documentation. These reactions may include a burning sensation, redness (erythema), mild skin irritation, and peeling (exfoliation).

Q: Is it normal to feel a mild burning sensation after applying Bifonazole?

A: A burning sensation at the application site is listed as a very common adverse reaction in official safety documentation. This reaction is generally localized and reversible, reflecting a common response to the topical application.

Q: Can Bifonazole cause skin irritation or redness?

A: Official regulatory documents list skin irritation and reddening (erythema) as common or very common reactions. These reactions are typically localized to the area where the product is applied and are documented in the adverse events profile.

Q: Can I use Bifonazole if I have sensitive skin?

A: Official warnings note that certain non-active ingredients, or excipients, within the formulation may cause local skin reactions like contact dermatitis. If using the product with sensitive skin, observing for signs of local irritation is generally suggested.

Q: Can Bifonazole interact with any other creams or lotions I'm using?

A: While the regulatory profile focuses on drug-drug interactions and an interaction with latex products, it is generally advised to clarify any potential effects with a healthcare professional regarding co-application of other topical products.

Q: Can Bifonazole be used on the scalp?

A: Official product information explicitly notes that this product is not recommended for the treatment of infections specifically affecting the scalp.

Q: Is Bifonazole used for nail fungal infections?

A: Bifonazole is indicated for treating certain fungal infections of the foot, including the exposed nail bed. Official information also notes that a combination product with urea is studied for the two-phase topical treatment of fungal nail infections (onychomycosis).

Q: Does Bifonazole cure the infection completely?

A: Regulatory information indicates that for a lasting outcome, treatment should be completed over the entire required duration, as described in product information. If the treatment is stopped too soon, the fungal infection may return.

Q: Can Bifonazole change the color or texture of the skin?

A: The official documentation lists certain skin reactions that affect appearance and texture. These adverse events include peeling (exfoliation), redness (erythema), and dry skin at the site of application.

Q: Does Bifonazole work against yeast infections (Candida)?

A: Official pharmacological information describes bifonazole as having a broad antimycotic spectrum. This spectrum includes various fungal pathogens, such as dermatophytes, molds, and yeasts like Candida.

Q: What happens when the use of Bifonazole is stopped?

A: Regulatory guidance emphasizes that if the complete course of treatment is interrupted or stopped prematurely, the underlying fungal infection may return or relapse, which underscores the importance of the defined treatment period.

Q: Does using a bandage or covering the area affect how Bifonazole works?

A: Official regulatory warnings state that occlusive (air-tight) bandages or dressings should not be used on the affected skin area after the cream is applied. This information is provided as a standard caution in the official product information.

Q: Is the absorption of Bifonazole into the body minimal?

A: Studies referenced in regulatory documents suggest that systemic absorption following topical application to healthy skin is generally low, measured at approximately 0.6% pm 0.3% of the dose. However, absorption may be increased if the product is applied to inflamed or broken skin.

Q: What are the main ingredients in a typical Bifonazole cream besides the active drug?

A: Official documents list the active drug, bifonazole, along with several non-active ingredients, or excipients. Common examples of these non-active components noted in regulatory listings include cetostearyl alcohol and benzyl alcohol.

Q: Can Bifonazole be used on broken or cracked skin?

A: Official warnings and precautions state the preparation is used with care on areas of denuded or broken skin. This caution is noted because absorption of the drug into the body may be increased through damaged skin.

Q: Is there a maximum time limit for using Bifonazole?

A: The required duration of treatment is defined by the specific fungal infection being addressed; for example, three weeks for Tinea pedis. It is expected that this duration will be completed to address the infection.

Q: Is it true that Bifonazole is used in combination with urea for some conditions?

A: Official information confirms the existence of a combination ointment containing bifonazole and urea. This product is specifically studied for the two-phase topical treatment of onychomycosis (fungal infections of the nail).

Q: Does Bifonazole have a specific mechanism compared to 'azole' antifungals?

A: Regulatory pharmacological documents indicate that bifonazole possesses a dual mechanism of action, a feature that distinguishes it from some other azole antifungal agents. This dual action inhibits the growth of fungi at two separate points in their cell membrane creation process.

Q: Is Bifonazole a treatment for dermatitis?

A: Dermatitis is not listed as a primary indication for treatment in official documents. Research has examined its use for conditions like seborrhoeic dermatitis, but official documents also list dermatitis as a possible adverse reaction.

Q: Can Bifonazole be used for ringworm (tinea corporis)?

A: Official product documents specify that bifonazole is used for treating dermatophytoses, which includes the fungal infection commonly known as ringworm (Tinea corporis).

How should Bifonazole be stored and disposed of?

How to Store and Dispose of Bifonazole

Official regulatory labeling dictates specific conditions for storing and disposing of Bifonazole to maintain its stability and ensure safety.

Storage Requirements

The product must generally be stored at room temperature, often defined as +15 C to +25 C (59 F to 77 F), and in a dry place. The drug substance is classified as light-resistant, but it must be kept in its original, tightly closed container to ensure protection from moisture and light. Consistent with national health authority guidelines, Bifonazole must always be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Bifonazole must follow local pharmaceutical waste regulations. The preferred method for discarding the medicine is through an official drug take-back program. It is a general regulatory requirement to not dispose of the product in wastewater (e.g., flushing down the toilet) to prevent environmental contamination.

Bifonazole